Literature DB >> 14598025

Two new regions of interest to evaluate separately cortical and trabecular BMD in the proximal femur using DXA.

Sven Prevrhal1, Margarita Meta, Harry K Genant.   

Abstract

To differentiate changes in trabecular and cortical bone density at a skeletal site bearing body weight, the main goal of this retrospective study was to develop and characterize two new regions of interest (ROIs) for DXA at the hip, one mainly focusing on trabecular bone and another mainly focusing on cortical bone. Specific aims were to maximize the precision of the ROIs and to characterize their usefulness for monitoring age-related bone loss and discriminating controls from fracture cases in a cross-sectional study population and to compare them with earlier ROIs designed by our group. The study used populations from two different previous studies conducted in our laboratory, with one comprising cohorts of healthy premenopausal women, healthy postmenopausal women, and postmenopausal osteoporotic women with at least one spinal fracture (Spine Fx Study) and the other one comprising two cohorts of age-matched postmenopausal women, in whom cases had sustained a hip fracture (Hip Fx study). The new ROI for trabecular bone (CIRCROI) tries to improve on the earlier custom-designed Central ROI, which was also targeted at trabecular bone. CIRCROI consists of an approximate largest circle that can fit inside the femoral proximal metaphysis without touching the superior and inferior endocortical walls. The new ROI for cortical bone (CORTROI) at a site bearing body weight is defined as a horizontal rectangular box crossing the femoral shaft below the lesser trochanter. CORTROI BMD cohort means were significantly higher than all other ROIs, and CIRCROI BMD cohort means were lower than standard ROIs with the exception of Ward's ROI. CIRCROI BMD was highly correlated with total femur BMD ( r=0.94) and Central BMD ( r=0.93), whereas CORTROI BMD correlations were lower (highest with total femur BMD ( r=0.86)). Fracture discrimination odds ratios (ORs) of all ROIs were significant for the Hip Fx Study, with CIRCROI BMD having the highest, and CORTROI BMD the lowest, OR (4.83 and 2.49 per SD, respectively, compared with 3.69 for Ward's ROI as the highest OR of standard ROIs). For the Spine Fx Study, only spinal and trochanteric BMD had significant OR. The new trabecular ROI had good short-term precision, comparable to the standard ROIs at the hip, but improving on that of Ward's triangle, the only standard ROI only including the anterior and posterior cortical walls and therefore more predominantly consisting of trabecular bone than other standard ROIs. The precision of the new cortical ROI was lower than standard DXA ROIs, except for Ward's triangle, but provides unique information on purely cortical bone at a skeletal site bearing body weight.

Entities:  

Mesh:

Year:  2003        PMID: 14598025     DOI: 10.1007/s00198-003-1500-6

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  29 in total

1.  Monitoring skeletal changes by radiological techniques.

Authors:  C C Glüer
Journal:  J Bone Miner Res       Date:  1999-11       Impact factor: 6.741

2.  Morphological and structural characteristics of the proximal femur in human and rat.

Authors:  C M Bagi; D Wilkie; K Georgelos; D Williams; D Bertolini
Journal:  Bone       Date:  1997-09       Impact factor: 4.398

Review 3.  Noninvasive assessment of bone mineral and structure: state of the art.

Authors:  H K Genant; K Engelke; T Fuerst; C C Glüer; S Grampp; S T Harris; M Jergas; T Lang; Y Lu; S Majumdar; A Mathur; M Takada
Journal:  J Bone Miner Res       Date:  1996-06       Impact factor: 6.741

4.  Effects of current and discontinued estrogen replacement therapy on hip structural geometry: the study of osteoporotic fractures.

Authors:  T J Beck; K L Stone; T L Oreskovic; M C Hochberg; M C Nevitt; H K Genant; S R Cummings
Journal:  J Bone Miner Res       Date:  2001-11       Impact factor: 6.741

5.  Prediction of vertebral and femoral strength in vitro by bone mineral density measured at different skeletal sites.

Authors:  X G Cheng; G Lowet; S Boonen; P H Nicholson; G Van der Perre; J Dequeker
Journal:  J Bone Miner Res       Date:  1998-09       Impact factor: 6.741

6.  Disparate effects of mild, moderate, and severe secondary hyperparathyroidism on cancellous and cortical bone in rats with chronic renal insufficiency.

Authors:  M A Miller; J Chin; S C Miller; J Fox
Journal:  Bone       Date:  1998-09       Impact factor: 4.398

7.  Assessment of the strength of proximal femur in vitro: relationship to femoral bone mineral density and femoral geometry.

Authors:  X G Cheng; G Lowet; S Boonen; P H Nicholson; P Brys; J Nijs; J Dequeker
Journal:  Bone       Date:  1997-03       Impact factor: 4.398

8.  Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group.

Authors:  S R Cummings; D M Black; M C Nevitt; W Browner; J Cauley; K Ensrud; H K Genant; L Palermo; J Scott; T M Vogt
Journal:  Lancet       Date:  1993-01-09       Impact factor: 79.321

9.  Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures.

Authors:  D Marshall; O Johnell; H Wedel
Journal:  BMJ       Date:  1996-05-18

10.  Regional differences in cortical porosity in the fractured femoral neck.

Authors:  K L Bell; N Loveridge; J Power; N Garrahan; B F Meggitt; J Reeve
Journal:  Bone       Date:  1999-01       Impact factor: 4.398

View more
  2 in total

1.  Assessment of the bilateral asymmetry of human femurs based on physical, densitometric, and structural rigidity characteristics.

Authors:  Melissa A Pierre; David Zurakowski; Ara Nazarian; Diana A Hauser-Kara; Brian D Snyder
Journal:  J Biomech       Date:  2010-07-07       Impact factor: 2.712

2.  Bone loss with antiepileptic drug therapy: a twin and sibling study.

Authors:  B Shiek Ahmad; S J Petty; A Gorelik; T J O'Brien; K D Hill; J J Christie; P N Sambrook; J D Wark
Journal:  Osteoporos Int       Date:  2017-06-06       Impact factor: 4.507

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.